Rossella Calori

TL;DR: In this paper, a multicenter GIMEMA study was conducted to correlate autoimmune complications (AIC) in B-cell chronic lymphocytic leukemia (B-CLL) with stage and therapy.

TL;DR: A prognostic model for overall survival (OS) based on the WHO criteria and BMF grading in 113 consecutive patients with chronic myeloproliferative disorders showed that the model is significantly associated with different OSs and, unlike the other PSSs, clearly discriminates the OS of intermediate- and high-risk patients.

TL;DR: The data indicate that, contrary to previous reports, Bcl-1 and B cl-2 rearrangements are not involved in CD5+ B-CLL pathogenesis and p53 mutations are present in 10% of cases at all stages of the disease.

TL;DR: Examination of microvessel density and immunohistochemical expression of vascular endothelial growth factor in the bone marrow biopsy specimens of 98 patients with Philadelphia chromosome-negative chronic myeloproliferative disorders could provide a rationale for directly targeting VEGF or endothelial cells in CIMF and PV.

TL;DR: CD34 immunostaining, which can be easily performed on routinely prepared BM biopsies, was found to be a powerful prognostic tool for predicting survival and outcome in MDS.